Antiparasitic therapy

Mayo Clinic Proceedings

Volumn 86, Issue 6, 2011, Pages 561-583

  Kappagoda, Shanthi ^a   Singh, Upinder ^a   Blackburn, Brian G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; BENZNIDAZOLE; CHLOROQUINE; CLINDAMYCIN; DILOXANIDE; DOXYCYCLINE; EFLORNITHINE; FLUCONAZOLE; FOLINIC ACID; HYDROXYCHLOROQUINE; MEFLOQUINE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; NITAZOXANIDE; PAROMOMYCIN; PENTAMIDINE; PYRIMETHAMINE; QUINIDINE; QUININE; STIBOGLUCONATE SODIUM; SULFADIAZINE; SURAMIN; TETRACYCLINE; UNINDEXED DRUG;

ABDOMINAL PAIN; ABSCESS; ACANTHAMOEBA; AFRICAN TRYPANOSOMIASIS; ALOPECIA; AMEBIASIS; ANGIOSTRONGYLUS CANTONENSIS; ANOREXIA; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIPARASITIC THERAPY; BABESIOSIS; BALAMUTHIA MANDRILLARIS; BLASTOCYSTIS HOMINIS; BLASTOCYSTOSIS; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANDIDIASIS; CAPILLARIA; CESTODE; CHAGAS DISEASE; CHILL; CLONORCHIASIS; COMBINATION CHEMOTHERAPY; CONGENITAL TOXOPLASMOSIS; CONTINUOUS INFUSION; CRYPTOSPORIDIOSIS; CUTANEOUS LARVA MIGRANS; CYCLOSPORIASIS; DERMATITIS; DIARRHEA; DIENTAMOEBA; DIPHYLLOBOTHRIUM LATUM; DISEASE SEVERITY; DIZZINESS; DRUG CHOICE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DYSGEUSIA; DYSPHORIA; ECG ABNORMALITY; ECHINOCOCCOSIS; ELECTROLYTE DISTURBANCE; ENTEROBIUS VERMICULARIS; EXFOLIATIVE DERMATITIS; FASCIOLIASIS; FILARIASIS; GIARDIASIS; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GNATHOSTOMIASIS; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HELMINTHIASIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYMENOLEPIS NANA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; ISOSPORIASIS; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; LOADING DRUG DOSE; LOIASIS; LYMPHATIC FILARIASIS; MALARIA FALCIPARUM; METHEMOGLOBINEMIA; MOOD CHANGE; MUSCLE RIGIDITY; MYALGIA; NAEGLERIA FOWLERI; NAUSEA; NEMATODE; NEPHROTOXICITY; NONHUMAN; ONCHOCERCIASIS; OPISTHORCHIASIS; OTOTOXICITY; PANCREATITIS; PARAGONIMIASIS; PARASITE TRANSMISSION; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PROTOZOAL INFECTION; PRURITUS; QRS COMPLEX; QT PROLONGATION; REVIEW; SCHISTOSOMIASIS; SEIZURE; SIDE EFFECT; SKIN LEISHMANIASIS; STRONGYLOIDES STERCORALIS; TAENIA SAGINATA; TAENIA SOLIUM; THROMBOCYTOPENIA; TOXOCARIASIS; TOXOPLASMOSIS; TREMATODE; TRICHINOSIS; TRICHOMONAS VAGINALIS; VERTIGO; VISCERAL LEISHMANIASIS; VIVID DREAM; VOMITING;

EID: 79957782677     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0203     Document Type: Review

References (133)

1. Centers for Disease Control and Prevention (CDC). Guidelines for treatment of malaria in the United States. http://www.cdc.gov/malaria/resources/ pdf/treatmenttable.pdf. Accessed April 29, 2011.
2. Maude RJ, Plewes K, Faiz MA, et al. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? Am J Trop Med Hyg. 2009;80:126-132.
3. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717-725. (Pubitemid 41207233)
4. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647-1657.
5. Centers for Disease Control and Prevention (CDC). Notice to readers: new medication for severe malaria available under an investigational new drug protocol. Morb Mortal Wkly Rep. 2007;56(30):769-770. http://www.cdc.gov/Mmwr/ preview/mmwrhtml/mm5630a5.htm. Accessed April 29, 2011.
6. Bethell D, Se Y, Lon C, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis. 2010;51:e105-e114.
7. Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J. 2010;9:238.
8. World Health Organization (WHO). Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010. 2nd ed. Geneva, Switzerland: World Health Organization; 2010. http://whqlibdoc.who.int/publications /2010/9789241500470-eng.pdf. Accessed April 29, 2011.
9. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-467.
10. Worldwide Antimalarial Resistance Network (WWARN). Web site http://www.wwarn.org/. Accessed April 29, 2011.
11. Valecha N, Looareesuwan S, Martensson A, et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis. 2010;51:684-691.
12. Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixeddose oral combination of pyronaridine-artesunate compared with artemether- lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375:1457-1467.
13. Thriemer K, Starzengruber P, Khan WA, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis. 2010;202:392-398.
14. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375:148-159.
15. Pepin J, Milord F, Guern C, Mpia B, Ethier L, Mansinsa D. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet. 1989;1:1246-1250. (Pubitemid 19140336)
16. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine co mbination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374:56-64.
17. Bisser S, N'Siesi FX, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis. 2007;195:322-329. (Pubitemid 46146108)
18. Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials. 2006;1:e39.
19. Brun R, Schumacher R, Schmid C, Kunz C, Burri C. The phenomenon of treatment failures in Human African Trypanosomiasis. Trop Med Int Health. 2001;6:906-914. (Pubitemid 33010877)
20. Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ. 2008;336:705-708. (Pubitemid 351481213)
21. Kibona SN, Matemba L, Kaboya JS, Lubega GW. Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania. Trop Med Int Health. 2006;11:144-155.
22. Torreele E. Fexinidazole: a rediscovered nitroimidazole drug candidate moving into clinical development for HAT. Presented at 57th ASTMH Annual Meeting. New Orleans, LA: December 7-11, 2008.
23. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA. 2007;298:2171-2181. (Pubitemid 350106656)
24. Lauria-Pires L, Braga MS, Vexenat AC, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg. 2000;63:111-118. (Pubitemid 32488345)
25. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010;115:55-68.
26. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348:1407-1413.
27. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998;59:526-529. (Pubitemid 28480704)
28. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a non- randomized trial. Ann Intern Med. 2006;144:724-734. (Pubitemid 46780632)
29. Marin-Neto JA, Rassi A Jr, Avezum A Jr, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009;104(suppl 1):319-324.
30. National Institutes of Health; National Library of Medicine; US Department of Health and Human Services. Clinical trial for the treatment of chronic Chagas disease with posaconazole and benznidazole (CHAGASAZOL). ClinicalTrials. Gov Web site. http://clinicaltrials.gov/ct2/show/NCT01162967. Accessed April 29, 2011.
31. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362:504-512.
32. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739-1746. (Pubitemid 35375612)
33. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005;366:1561-1577. (Pubitemid 41540115)
34. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31:1104-1107. (Pubitemid 32299375)
35. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356:2571-2581. (Pubitemid 46961002)
36. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect Dis. 2010;10:184-194.
37. Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg. 2007;77:89-94. (Pubitemid 351844356)
38. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377:477-486.
39. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009;CD004834.
40. Soto J, Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg. 2006;100(suppl 1):S34-S40. (Pubitemid 44490170)
41. van der Meide WF, Sabajo LO, Jensema AJ, et al. Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname. Int J Dermatol. 2009;48:52-58.
42. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346:891-895. (Pubitemid 34984637)
43. Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg. 2007;76:48-52. (Pubitemid 351627801)
44. van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis. 2010;50: 80-83.
45. Miranda-Verastegui C, Tulliano G, Gyorkos TW, et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis. 2009;3:e491.
46. Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol. 2006;142:1575-1579. (Pubitemid 44969213)
47. Wortmann G, Zapor M, Ressner R, et al. Liposomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg. 2010; 83:1028-1033.
48. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis. 2007;44:788-793. (Pubitemid 46365302)
49. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007;44:350-356. (Pubitemid 46147616)
50. Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol. 2010;2010:617521. http://www.hindawi.com/journals/jbb/2010 /617521/. Accessed April 29, 2011.
51. Wasunna MK, Rashid JR, Mbui J, et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg. 2005;73:871-876. (Pubitemid 41688461)
52. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089-1134. (Pubitemid 44637131)
53. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000;343:1454-1458.
54. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46:370-376. (Pubitemid 351263520)
55. Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis. 2010;50:381-386.
56. Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112:1876-1882.
57. Torre D, Casari S, Speranza F, et al; Italian Collaborative Study Group. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine- sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1998;42:1346-1349.
58. Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47:554-566.
59. Thiebaut R, Leproust S, Chene G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet. 2007;369:115-122.
60. Busatti HG, Santos JF, Gomes MA. The old and new therapeutic approaches to the treatment of giardiasis: where are we? Biologics. 2009;3:273-287.
61. Rossignol JF. Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp Parasitol. 2010;124:45-53.
62. Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, Singer SM. A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis. 2010;4:e682.
63. Gonzales ML, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2009;CD006085.
64. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg. 2007;101:1025-1031. (Pubitemid 47317236)
65. Cabada MM, White AC Jr. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis. 2010;23:494-499.
66. Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. 2007;CD004932.
67. Gargala G, Le Goff L, Ballet JJ, Favennec L, Stachulski AV, Rossignol JF. Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum. Antimicrob Agents Chemother. 2010;54:1315-1318.
68. Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim- sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients: a randomized, controlled trial. Ann Intern Med. 2000;132:885-888. (Pubitemid 30346851)
69. Zimmer SM, Schuetz AN, Franco-Paredes C. Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. Clin Infect Dis. 2007;44: 466-467. (Pubitemid 46147638)
70. Weiss LM, Perlman DC, Sherman J, Tanowitz H, Wittner M. Isospora belli infection: treatment with pyrimethamine. Ann Intern Med. 1988;109:474-475.
71. Romero Cabello R, Guerrero LR, Munoz Garcia MR, Geyne Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans R Soc Trop Med Hyg. 1997;91:701-703. (Pubitemid 28019920)
72. Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg. 2010;82:614-619.
73. Rossignol JF, Kabil SM, Said M, Samir H, Younis AM. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin Gastroenterol Hepatol. 2005;3:987-991. (Pubitemid 41415746)
74. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1-110.
75. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50:4209-4210. (Pubitemid 44865173)
76. Mammen-Tobin A, Wilson JD. Management of metronidazole-resistant Trichomonas vaginalis - a new approach. Int J STD AIDS. 2005;16:488-490. (Pubitemid 41003150)
77. Tayal SC, Ochogwu SA, Bunce H. Paromomycin treatment of recalcitrant Trichomonas vaginalis. Int J STD AIDS. 2010;21:217-218.
78. Schuster FL, Visvesvara GS. Opportunistic amoebae: challenges in prophylaxis and treatment. Drug Resist Updat. 2004;7:41-51. (Pubitemid 38453835)
79. Vargas-Zepeda J, Gomez-Alcala AV, Vasquez-Morales JA, Licea-Amaya L, De Jonckheere JF, Lares-Villa F. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch Med Res. 2005;36:83-86. (Pubitemid 40386355)
80. Saxena A, Mittal S, Burman P, Garg P. Acanthameba meningitis with successful outcome. Indian J Pediatr. 2009;76:1063-1064.
81. Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis. 2008;14:1743-1746.
82. Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted Balamuthia mandrillaris - Arizona, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:1182.
83. Schuster FL, Yagi S, Gavali S, et al. Under the radar: Balamuthia amebic encephalitis. Clin Infect Dis. 2009;48:879-887.
84. Deetz TR, Sawyer MH, Billman G, Schuster FL, Visvesvara GS. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis. 2003;37:1304-1312. (Pubitemid 37433625)
85. Martinez DY, Seas C, Bravo F, et al. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. Clin Infect Dis. 2010;51:e7-e11.
86. Lateef M, Zargar SA, Khan AR, Nazir M, Shoukat A. Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide. Int J Infect Dis. 2008;12:80-82. (Pubitemid 350299228)
87. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004;350:249-258. (Pubitemid 38067637)
88. Chero JC, Saito M, Bustos JA, Blanco EM, Gonzalvez G, Garcia HH. Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions. Trans R Soc Trop Med Hyg. 2007;101:203-205. (Pubitemid 44848175)
89. Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W. Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China. Acta Trop. 2005;94:1-14. (Pubitemid 40450294)
90. Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114:1-16.
91. Bygott JM, Chiodini PL. Praziquantel: neglected drug? ineffective treatment? or therapeutic choice in cystic hydatid disease? Acta Trop. 2009;111:95-101.
92. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368:1106-1118. (Pubitemid 44402679)
93. Boulanger D, Dieng Y, Cisse B, et al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans R Soc Trop Med Hyg. 2007;101:113-116. (Pubitemid 44848173)
94. Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect Dis. 2007;7:218-224. (Pubitemid 46274518)
95. Ismail M, Botros S, Metwally A, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999;60:932-935. (Pubitemid 29296217)
96. Ferrari ML, Coelho PM, Antunes CM, Tavares CA, da Cunha AS. Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bull World Health Organ. 2003;81:190-196. (Pubitemid 36372957)
97. Moll L, Gaasenbeek CP, Vellema P, Borgsteede FH. Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The Netherlands. Vet Parasitol. 2000;91:153-158. (Pubitemid 30411964)
98. Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther. 2003;17:265-270. (Pubitemid 36174258)
99. Bunnag D, Harinasuta T. Studies on the chemotherapy of human opisthorchiasis in Thailand: I. Clinical trial of praziquantel. Southeast Asian J Trop Med Public Health. 1980;11:528-531.
100. Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. Chin Med J (Engl). 1991;104:27-31.
101. Soukhathammavong P, Odermatt P, Sayasone S, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. Lancet Infect Dis. 2011;11:110-118.
102. Udonsi JK. Clinical field trials of praziquantel in pulmonary paragonimiasis due to Paragonimus uterobilateralis in endemic populations of the Igwun Basin, Nigeria. Trop Med Parasitol. 1989;40:65-68.
103. Calvopina M, Guderian RH, Paredes W, Chico M, Cooper PJ. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans R Soc Trop Med Hyg. 1998;92:566-569. (Pubitemid 28486493)
104. Kim JS. Treatment of Paragonimus westermani infections with bithionol. Am J Trop Med Hyg. 1970;19:940-942.
105. Bunnag D, Radomyos P, Harinasuta T. Field trial on the treatment of fasciolopsiasis with praziquantel. Southeast Asian J Trop Med Public Health. 1983;14:216-219. (Pubitemid 14226227)
106. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA. 2008;299:1937-1948. (Pubitemid 351574924)
107. Knopp S, Mohammed KA, Speich B, et al. Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. Clin Infect Dis. 2010;51:1420-1428.
108. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, Taylor M. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ. 2003;81:343-352. (Pubitemid 36644260)
109. Galvan-Ramirez ML, Rivera N, Loeza ME, et al. Nitazoxanide in the treatment of Ascaris lumbricoides in a rural zone of Colima, Mexico. J Helminthol. 2007;81:255-259. (Pubitemid 47417545)
110. Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg. 2003;68:384-385. (Pubitemid 38230634)
111. Wen LY, Yan XL, Sun FH, Fang YY, Yang MJ, Lou LJ. A randomized, double-blind, multicenter clinical trial on the efficacy of ivermectin against intestinal nematode infections in China. Acta Trop. 2008;106:190-194.
112. Matsen JM, Turner JA. Reinfection in enterobiasis (pinworm infection). Simultaneous treatment of family members. Am J Dis Child. 1969;118:576-581.
113. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sanchez-Sanchez P, Matogo-Oyana J, Rodriguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother. 2004;5:2615-2619. (Pubitemid 39646523)
114. Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg. 1996;55:477-481. (Pubitemid 26392708)
115. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17:208-217. (Pubitemid 38120934)
116. Turner SA, Maclean JD, Fleckenstein L, Greenaway C. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg. 2005;73:911-914. (Pubitemid 41688467)
117. Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis. 2005;41:e5-e8.
118. Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health. 2004;35:531-534. (Pubitemid 39486416)
119. Watt G, Saisorn S, Jongsakul K, Sakolvaree Y, Chaicumpa W. Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis. J Infect Dis. 2000;182:371-374. (Pubitemid 30497835)
120. Sturchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol. 1989;83:473-478. (Pubitemid 19254070)
121. Magnaval JF. Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis. Parasitology. 1995;110(pt 5):529-533.
122. Barisani-Asenbauer T, Maca SM, Hauff W, et al. Treatment of ocular toxocariasis with albendazole. J Ocul Pharmacol Ther. 2001;17:287-294. (Pubitemid 32656549)
123. Centers for Disease Control and Prevention (CDC). Parasites-lymphatic filariasis: guidance for evaluation and treatment. http://www.cdc.gov/parasites/ lymphaticfilariasis/health-professionals/dxtx.html. Accessed April 29, 2011.
124. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis. 2008;21:673-681.
125. Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. Clin Infect Dis. 2007;44:53-60. (Pubitemid 44968984)
126. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010;376:1175-1185.
127. Padgett JJ, Jacobsen KH. Loiasis: African eye worm. Trans R Soc Trop Med Hyg. 2008;102:983-989.
128. Klion AD, Massougbodji A, Horton J, et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis. 1993;168:202-206.
129. Albanese G, Venturi C, Galbiati G. Treatment of larva migrans cutanea (creeping eruption): a comparison between albendazole and traditional therapy. Int J Dermatol. 2001;40:67-71. (Pubitemid 32201238)
130. Chotmongkol V, Wongjitrat C, Sawadpanit K, Sawanyawisuth K. Treatment of eosinophilic meningitis with a combination of albendazole and corticosteroid. Southeast Asian J Trop Med Public Health. 2004;35:172-174. (Pubitemid 38860078)
131. Pai PJ, Blackburn BG, Kazacos KR, Warrier RP, Begue RE. Full recovery from Baylisascaris procyonis eosinophilic meningitis. Emerg Infect Dis. 2007;13:928-930. (Pubitemid 46890146)
132. Nontasut P, Bussaratid V, Chullawichit S, Charoensook N, Visetsuk K. Comparison of ivermectin and albendazole treatment for gnathostomiasis. Southeast Asian J Trop Med Public Health. 2000;31:374-377.
133. Cross JH. Intestinal capillariasis. Clin Microbiol Rev. 1992;5:120-129.